Compare STTK & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | CNNE |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.4M | 497.5M |
| IPO Year | 2020 | 2017 |
| Metric | STTK | CNNE |
|---|---|---|
| Price | $6.95 | $12.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $7.60 | ★ $21.33 |
| AVG Volume (30 Days) | 502.9K | ★ 692.7K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 4.81% |
| EPS Growth | ★ 53.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,000,000.00 | ★ $499,700,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3.37 |
| 52 Week Low | $0.71 | $10.46 |
| 52 Week High | $7.68 | $21.96 |
| Indicator | STTK | CNNE |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 58.74 |
| Support Level | $5.75 | $11.54 |
| Resistance Level | N/A | $16.41 |
| Average True Range (ATR) | 0.47 | 0.45 |
| MACD | 0.03 | 0.24 |
| Stochastic Oscillator | 61.66 | 85.84 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.